Therapeutic Response

ER positive and HER2-negative status confers therapeutic sensitivity to Datopotamab deruxtecan in patients with Invasive Breast Carcinoma.

Statements

Source and description

Datroway (datopotamab deruxtecan-dlnk) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to datopotamab deruxtecan-dlnk for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.